Specifications
- Purity
- ≥97% (HPLC)
- Appearance
- White to off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO, ethanol
Downloads
- Safety Data Sheet
- CDX D0371 MSDS.pdf
Category: Antibiotics
Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the β-tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.
Synonyms | Taxotere®, NSC 628503, RP 56976, N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol |
---|---|
Purity | ≥97% (HPLC) |
Appearance | White to off-white powder |
CAS-Number | 114977-28-5 |
Molecular Formula | C43H53NO14 |
Molecular Weight | 807.88 |
Identity | 1H-NMR |
Solvents | DMSO, ethanol |
Smiles | CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C |
InChi Key | ZDZOTLJHXYCWBA-VCVYQWHSSA-N |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Transportation | Not dangerous goods |
References | (1) M.C. Bissery, et al., Cancer Res. 51, 4845 (1991), (2) R. Bruno & G.J. Sanderink, Cancer Surv. 17, 305 (1993) (Review), (3) K. Gelmon, Lancet 344, 1267 (1994) (Review), (4) M.E. Trudeau, Can. J. Oncol. 6, 443 (1996) (Review), (5) I.A. Avramis, et al., Anticancer Res. 21, 2281 (2001), (6) M. Aapro & E. Rowinsky, Anticancer Drugs 12, S1 (2001) (Review), (7) P.B. Cassidy, et al., Clin. Cancer Res. 8, 846 (2002), (8) M.S. Si, et al., Invest. New Drugs 21, 281 (2003), (9) B. Ramaswamy & S. Puhalla, Drugs Today 42, 265 (2006) (Review), (10) H. Hernandez-Vargas, et al., Cell Cycle 6, 780 (2007) (Review), (11) H. Ching-Hsia, et al., Toxicol. Sci. 145, 59 (2015) |
InChi | InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1 |
Quantity | 5 mg, 25 mg, Bulk |